ARA Injection Pen

ARA-290, also known as cibinetide, is a small 11-amino-acid peptide given as a subcutaneous injection. It is a modified, non-blood-building fragment of the body's natural EPO signal.

• Activates the Innate Repair Receptor — a receptor the body upregulates at sites of injury and inflammation.
• Non-Erythropoietic — unlike blood-building EPO, it is not expected to raise red blood cell count or blood pressure.
• Supports Nerve Repair — engages the pathways involved in tissue and nerve recovery.
• Calms Inflammation — the repair receptor it targets is part of the body's own inflammation-resolving system.
• Daily Signaling — works dose by dose, which is why the protocol is once daily.

This is the key distinction. Standard EPO is erythropoietic, meaning it stimulates red blood cell production, which is why it raises hematocrit and can affect blood pressure. ARA-290 is derived from a different region of the EPO molecule that engages only the Innate Repair Receptor.

That means it targets the tissue-protective and repair signaling associated with EPO without the blood-building effect. It is not expected to raise your red blood cell count or blood pressure. That separation of effects is the entire reason a modified peptide like ARA-290 exists.

The program is built in two steps. Week 1 is an induction phase at 40 units (about 2.1mg) once daily, which lets your body acclimate to daily dosing before stepping up. From week 2 through week 12 you move to the maintenance dose of 75 units (4mg) once daily.

This titrated start is a standard way to ease into a daily peptide protocol and is one of the habits that keeps side effects mild. Your pen counts the units for you, so you simply dial to the number for the week you are in.

Yes. ARA-290 pen injector contains no toxic fillers or preservatives. Each batch is prepared in a 503A licensed compounding pharmacy under the supervision of Dr. Sasson Moulavi, MD — physician-formulated for consistent purity and potency, and third-party tested with a COA available upon request.

Inject once daily at about the same time each day. Week 1: dial to 40 units (about 2.1mg). Weeks 2 through 12: dial to 75 units (4mg). Inject subcutaneously into the abdomen, at least 2 inches from the navel, or the front of the thigh, rotating your spot each day so the same skin does not get sore.

After pressing the button and the dial returns to zero, count to 10 before removing the needle to ensure the full dose is delivered. Always prime the pen when loading a new cartridge. Full step by step instructions are in the Administration Protocol panel.

Yes, every time you load a new cartridge into the reusable pen it must be primed once before the first dose. With the needle attached and uncovered, turn the dial 5 to 10 clicks until the plunger moves close to the bottom stopper, then dial and press 1 to 2 clicks until a drop of fluid appears at the needle tip.

Some cartridges, especially those with less than 3mL remaining, may need several rounds of 20 to 30 clicks to get the plunger moving. Once primed, no further priming is needed until the next new cartridge is loaded.

ARA-290 is generally well tolerated. Because it activates a repair receptor and does not build red blood cells, it has been well tolerated in studies. When side effects occur they are usually mild and settle on their own: mild redness, itching, or soreness at the injection site, which rotating your spot each day helps reduce, and occasionally a headache or a temporary feeling of warmth or flushing.

Unlike blood-building EPO, ARA-290 is not expected to raise red blood cell count or blood pressure. Tell your provider about any new or persistent symptoms.